

Recommended high purity components for SEDDS and SMEDDS development:


Carrier oils	Primary surfactant	Co-solvents	Co-surfactants
Super Refined™ Castor Oil	Super Refined™ CCMG 400	Super Refined™ DEGEE	Cithrol™ GMO HP
Super Refined™ Corn Oil	Super Refined™ GMCC	Super Refined™ DMI-P	Span™ 20 HP
Super Refined™ Cottonseed Oil	Super Refined™ L18 POG	Super Refined™ PEG 300	Span™ 60 HP
Super Refined™ GMCC	Super Refined™ O18 POG	Super Refined™ PEG 400	Span™ 80 HP
Super Refined™ GTCC	Super Refined™ P35 Castor Oil	Super Refined™ PEG 600	
Super Refined™ Oleic Acid	Super Refined™ PGML	Super Refined™ Propylene Glycol	
Super Refined™ Olive Oil	Super Refined™ Polysorbate 20		
Super Refined™ Peanut Oil	Super Refined™ Polysorbate 60		
Super Refined™ Safflower	Super Refined™ Polysorbate 80		
Super Refined™ Sesame Oil			
Super Refined™ Soybean			

Super Refined offering (listed in alphabetical order by chemical description):


Chemical description	Product name	USP/NF	Ph. Eur.	JPE/JP	FDA IID*	ChP
Benzyl Alcohol	Super Refined™ Benzyl Alcohol	■	■	■	■	
Caprylic/Capric Triglyceride	Super Refined™ GTCC	■	■	■	■	■
Caprylocaproyl Polyoxylglycerides	Super Refined™ CCMG 400	■	■		■	
Castor Oil	Super Refined™ Castor Oil	■		■		■
Corn Oil	Super Refined™ Corn Oil	■	■		■	
Cottonseed Oil	Super Refined™ Cottonseed	■			■	
Diethylene Glycol Monoethyl Ether	Super Refined™ DEGEE	■	■			
Dimethyl Isosorbide	Super Refined™ DMI-P	†				
Glyceryl Monocaprylocaprates	Super Refined™ GMCC	■	■		■	
Linoleoyl Polyoxylglycerides	Super Refined™ L18 POG	■	■		■	
Oleic Acid	Super Refined™ Oleic Acid			■	■	
Oleoyl Polyoxylglycerides	Super Refined™ O18 POG	■	■			
Olive Oil	Super Refined™ Olive Oil	■	■	■	■	
Peanut Oil	Super Refined™ Peanut	■	■		■	
Petrolatum	Super Refined™ Petrolatum	■	■	■	■	■
Polyethylene Glycol 300	Super Refined™ PEG 300	■	■	■	■	
Polyethylene Glycol 400	Super Refined™ PEG 400	■	■	■	■	
Polyethylene Glycol 600	Super Refined™ PEG 600	■	■	■	■	
Polyoxyl 35 Castor Oil	Super Refined™ P35 Castor Oil	■	■	■	■	
Polysorbate 20	Super Refined™ Polysorbate 20	■	■	■	■	■
Polysorbate 60	Super Refined™ Polysorbate 60	■	■	■	■	
Polysorbate 80	Super Refined™ Polysorbate 80	■	■	■	■	■
Polysorbate 80	Super Refined™ Polysorbate 80 A				■	■
Propylene Glycol	Super Refined™ Propylene Glycol	■		■	■	
Propylene Glycol Monolaurate Type II	Super Refined™ PGML	■	■		■	
Safflower Oil	Super Refined™ Safflower Oil	■				
Sesame Oil	Super Refined™ Sesame Oil	■	■	■	■	■
Soybean Oil	Super Refined™ Soybean Oil	■	■	■	■	
White Wax (Beeswax)	Super Refined™ Beeswax	■	■	■	■	

*FDA IID listing for oral dosage forms only


†Monograph pending




Small Molecule Delivery



Protein Delivery



Nucleic Acid Delivery



Adjuvant Systems

Empowering biologics delivery

References

¹Gatchalian N., Joseph L.B., Westergom C.M., Langley N.A. The Purity of PEG 400 Affects the Stability of Gelatin Capsules. Poster presented at: AAPS Annual Meeting and Exposition; 2005 Nov 6-10; Nashville, TN.

²Kaziska A., Grant C. Taste Testing of Oral Dose Excipients – Comparing Chromatographically Purified and Standard Products. Poster T2259 presented at: AAPS Annual Meeting and Exposition; 2015 Oct 25-29; Orlando, FL.

³Hall N., Humphrey J., Radwick A., Rumbelow S. Designing Self-Emulsifying Lipid-Based Formulations for Drug Delivery with Purified Excipients. Poster 28W0300 presented at: AAPS Annual Meeting and Exposition; 2016 Nov 13-17; Denver, CO.



www.crodapharma.com

Europe, Middle East & Africa: pharma.emea@croda.com

North America: pharma.usa@croda.com

Asia Pacific: pharma.asia@croda.com

Latin America: pharma.latam@croda.com

Non-warranty

The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third-party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Unless otherwise stated, any trademarks identified herein are trademarks of the Croda group of companies.



Super Refined™ excipients for oral drug delivery

Oral drug development of both new and existing chemical entities often face numerous challenges including poor solubility, formulation instability and ineffective drug delivery. Regardless of the challenge, the ultimate goal is to create successful drug products with shortened development timelines. The selection of the right oral excipient during early phase development is critical to achieve this goal.

Croda's Super Refined proprietary process creates highly purified excipients that deliver benefits when formulating an oral drug product. These formulation benefits can then be translated into increased final drug value.

Benefits and features:

- Improved API stability
- Increased gelatine capsule stability
- Improved taste impact
- Reduced colour impurities
- Creation of SEDDS & SMEDDS
- Low peroxide values
- Low moisture
- Multi-compendial – USP/NF, Ph. Eur. JPE and ChP

Drug value:

- Enhanced drug performance and stability
- Improved shelf life
- Increased patient compliance
- Improved bioavailability
- Decreased formulation development time
- Decreased time to market

Increased drug stability

Stabilisation of an Active Pharmaceutical Ingredient (API) is crucial to successful drug development. As API degradation can be initiated and accelerated by impurities that can be introduced by excipients in the formulation, carefully selecting the right oral excipient can be essential to formulation success.

To demonstrate enhanced API stability, the degradation of Vitamin K₁ in Super Refined P35 Castor Oil was compared with that in standard compendial P35 castor oil over a 12 week period at 40°C.

Using Liquid Chromatography-Mass Spectrometry (LC-MS), it can be seen (Figure 1) that the Vitamin K₁ in Super Refined P35 Castor Oil exhibited up to 85% drug recovery while the same API in compendial P35 castor oil showed the majority (if not all) of the vitamin has degraded. The study clearly demonstrates that Super Refined P35 Castor Oil improves drug stability of the API over compendial P35 castor oil.




Figure 1: Comparison of Vitamin K₁ recovery in Super Refined P35 Castor Oil as compared to compendial P35 castor oil over a 12 week period at 40°C

Improved gelatine capsule stability

Over time, the impurities found in commonly used solvents and fillers in gelatine capsules can preferentially absorb moisture from the gelatine shell. This moisture absorption can cause the gelatine to crosslink which, ultimately, cause the capsule to harden. The hardening of the capsule can result in either cracking or longer disintegration times leading to unacceptable drug efficacy.

To demonstrate that the lower impurity profile of Super Refined PEG 400 reduces crosslinking and decreases hardening of gelatine capsules, solutions were made containing 1 part gelatine (1% w/v in water) and 2 parts PEG 400¹. Compendial grade PEG 400 NF gelatine solutions were compared to gelatine solutions made with Super Refined PEG 400. The solutions were centrifuged at 3,500 rpm and 10,000 rpm for 10 minutes with the level of precipitation used as an indicator of crosslinking.




Figure 2: Comparison of gelatine dissolved in Super Refined PEG 400 vs. standard compendial grade, centrifuged at 3,500 rpm

It can be seen in Figure 2 and 3 that the Super Refined PEG 400 keeps the gelatine in suspension while the impurities in the standard grade PEG 400 NF cause the gelatine to crosslink forming a precipitate which is clearly observed upon centrifugation.

Reduced taste impact

The impact of an excipient on the taste of an oral drug can significantly affect patient compliance and repeat purchase. To demonstrate that Super Refining can help minimise the taste impact of excipients, a 3rd party testing company (Sensory Spectrum, Inc.) was contracted to quantitatively identify the degree of difference in taste between Super Refined Polysorbate 80 and its standard compendial counterpart. A taste panel of extensively trained taste specialists assigned a Degree of Difference comparing Super Refined Polysorbate 80 to the control. The Degree of Difference (DOD) scores ranged from 0 – 10 with 0 indicating no difference and a 10 indicating an extreme difference. A DOD of 5 or higher indicates that consumers will be able to distinctly perceive a difference in taste.




Figure 4: Taste impact and DOD of Super Refined Polysorbate 80 as compared to standard pharmaceutical grade of polysorbate 80

As seen in Figure 4, the DOD for Super Refined Polysorbate 80 versus its standard compendial equivalent was an 8. With a DOD of 8, it is clear that there is a significant consumer-perceivable taste difference between the Super Refined Polysorbate 80 and the control. The qualitative results demonstrated that the Super Refined Polysorbate 80 had a much lower taste impact than the standard compendial grade. Thus, the use of Super Refined Polysorbate 80 will allow formulators greater flexibility when creating more palatable oral liquid dosage forms to promote better patient compliance.

Reduced colour impact & impurities

The Super Refining process yields a highly purified excipient with a reduction in both colour and overall impurity levels. The purification of oral excipients yields improved drug appearance as well as improved stability of the excipient; the API and drug formulation results in enhanced product performance.

In Figure 5, the colour impact of the Super Refined process can be clearly seen. In addition, the Super Refining process yields significant reductions in multiple impurities including aldehydes, ketones, lower chain fatty acids and hydrocarbons (Figure 6).




Figure 5: Beeswax before and after the Super Refining process

Detected impurities	Impurity reduction through Super Refining (%)
Hydrocarbons (such as Undecane, Dodecane, Pentadecane, Tetradecane, etc.)	82-100%
Aldehydes (such as 3-Methylbutanal, Octanal, Dodecanal, etc.)	90-100%
Lower Chain Fatty Acids (such as Acetic acid, Butanoic acid, Pentanoic acid, Hexanoic acid, etc)	82-100%
Lower Chain Alcohols (such as Ethanol, 2-Heptanol, Nonanol, etc.)	77-100%

Figure 6: Detected impurities by GC-MS that were reduced during the Super Refining process

Expanded options for SEDDS & SMEDDS

Self-emulsifying drug delivery systems (SEDDS) and self-microemulsifying drug delivery system (SMEDDS) are lipid-based formulations that aim to deliver hydrophobic drugs that typically are associated with poor water solubility and low bioavailability. In order to design and streamline the development of SEDDS and SMEDDS, ternary phase diagrams were developed to determine optimum blends between surfactant to co-system (surfactant or solvent) and surfactant to oil in the purified excipient combinations selected (Figure 7)⁴.

Pure surfactant and certain surfactant to co-system ratios when diluted in distilled water [fasted (1:50) and fed (1:250)] exhibited similar particle sizes with an approximate z average less than 50 d.nm. As the Super Refined Polysorbate 20 or 80 concentration decreased and the Etocas™ 35 pharma or Super Refined PEG 300 or 400 concentration increased, the particle size distribution was observed to be multimodal.




Figure 7: Phase diagrams of diluted, purified surfactants (Super Refined Polysorbate 20 or 80) co-surfactant (Etocas 35 pharma*), co-solvents (Super Refined PEG 300 and 400) and oils (Super Refined Oleic Acid or Crodamol GTCC pharma*) in distilled water. [Green = SMEDDS (particle size of <50 nm); Light blue = SEDDS (particle size of 100-300 nm)]

Through the development of these phase diagrams, it was determined that purified surfactants, co-surfactants, co-solvents and oils enable the formation of a wide range of colloidal phases including micelles, microemulsions (oil-in-water; water-in oil, bicontinuous) and liquid crystals (lamellar and hexagonal). This work can, in turn, be used to design custom-made, purified, lipid-based formulations.

⁴Etocas 35 pharma (co-surfactant) and Crodamol GTCC pharma (carrier oil) are exclusive trademarked excipients of Croda